BETHPAGE, NY, September 30, 2010 (Press-News.org) With sales quota achievement at an all-time low and the worst economic downturn in memory, Find New Customers, a B2B sales and marketing automation consultancy, announces a series of webinars with top B2B marketing thought leaders. The "B2B Demand Generation Thought Leadership Series" is designed to help B2B companies develop the strategies and tactics necessary to increase sales-ready leads and close more business. The lineup of B2B marketing experts will be announced in early October. More information about the webinar series can be found at http://www.FindNewCustomers.com/B2B-webinar.
Paige O'Neill, VP of Corporate Marketing and Communications at Aprimo, says "We reached out to Find New Customers because of their remarkably broad and deep network of top marketing experts. Find New Customers is uniquely qualified to bring marketing professionals insightful thought leadership across several important marketing areas, including sales and demand generation."
Jeff Ogden, President of Find New Customers (http://www.findnewcustomers.com), says "With sales results slumping, it's clear business sellers are looking for fresh ideas and insights. This webinar series will connect them with top experts with those fresh idea and insights they so badly need.
Ogden, a sales and marketing expert, employs best practices in lead generation to help companies acquire customers and crush competitors via demand generation programs. His proven track record of exceeding targets speaks to his fearless competitor attitude and results-oriented nature. Jeff's recent works include popular white papers and eBooks including "How to Find New Customers", "Definitive Guide to Making Quote" and "Moving from Transactional to Conversational Email Marketing" (http://www.findnewcustomers.com/getcustomers).
About Find New Customers LLC
Find New Customers (http://www.findnewcustomers.com/) helps businesses implement demand generation programs and processes to grow revenue through quality sales leads. Company president, Jeff Ogden, is also the author of highly regarded white papers on topics such as demand generation, sales and email marketing. (www.findnewcustomers.com). In addition, he writes a popular blog, Fearless Competitor (www.fearlesscompetitor.net).
Find New Customers Announces Webinar Series on B2B Marketing and Demand Generation
Seven out of 10 companies say lack of quality sales leads is no. 1 problem; "B2B Demand Generation Thought Leadership Series" designed to teach companies how to increase sales-ready leads.
2010-09-30
ELSE PRESS RELEASES FROM THIS DATE:
Guide to Natural Eczema Treatments Hits the Market - From Eczema Free Forever TM
2010-09-30
Eczema Free Forever TM provides answers to practical, homemade and natural solutions, that the eczema suffering population in any part of the world can easily perform in the comfort of their home.
One in eight people suffer from eczema in the U.S. That's 15 million people. What causes eczema? Which eczema treatment works best? These are questions that the millions of people with the condition ask regularly.
There certainly is no shortage of medicines available on the market that lay claim to being the absolute best cure for eczema. The creams and oily goop that pass ...
Triple-negative breast cancers may have unique therapeutic target
2010-09-29
DENVER — Patients with triple-negative breast cancer, one of the hardest subtypes to treat, may have a unique biomarker that would enable them to receive more targeted therapy, according to data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
Triple-negative breast cancers are breast cancers that have tested negative for estrogen receptors, progesterone receptors and HER2. Because of this biology, these cancers do not respond to endocrine therapies or trastuzumab.
"In other subsets of breast cancer, ...
Circulating tumor cells can provide 'real-time' information on patient's current disease state
2010-09-29
DENVER — Circulating tumor cells (CTCs) may be a promising alternative, noninvasive source of tumor materials for biomarker assessment, according to data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
"The basic idea is that CTCs can provide real-time information about a patient's current disease state, acting as a 'liquid biopsy,'" said Siminder Kaur Atwal, Ph.D., senior research associate at Genentech. "They are much less invasive than tumor biopsies because they can be detected from a blood draw and ...
Biomarker panel identifies prostate cancer with 90 percent accuracy
2010-09-29
DENVER — Researchers in England say they have discovered a set of biomarkers that can distinguish prostate cancer from benign prostate disease and healthy tissue with 90 percent accuracy. This preliminary data, if validated in larger ongoing studies, could be developed into a serum protein test that reduces the number of unnecessary biopsies and identifies men who need treatment before symptoms begin.
The researchers, from Oxford Gene Technology (OGT) and its subsidiary, Sense Proteomic, Ltd., presented their findings at the Fourth AACR International Conference on Molecular ...
New biomarkers discovered for pancreatic cancer and mesothelioma
2010-09-29
DENVER — Using a novel aptamer-based proteomics array technology, researchers and collaborators have identified biomarkers and protein signatures that are hallmarks of cancer at an early stage for two of the most aggressive and deadly forms of cancer — pancreatic and mesothelioma.
This technology would enable better clinical diagnosis at an earlier stage and may provide insight into new therapeutic targets, said Rachel Ostroff, Ph.D., clinical research director of Somalogic Inc.
"Currently these cancers are detected at an advanced stage, where the possibility of cure ...
African-Americans equally likely to benefit from erlotinib and other targeted lung cancer therapy
2010-09-29
DENVER — African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib.
"This study has immediate implications for patient management. Patients with EGFR mutations have a much better prognosis and respond better to erlotinib than those who do not," said Ramsi Haddad, Ph.D., director of the Laboratory of Translational Oncogenomics at the Barbara Ann Karmanos Cancer Institute, and assistant ...
Novel biomarker may predict response to new VEGF receptor inhibitor
2010-09-29
DENVER — Researchers believe there may be a way to predict, based on individual tumors, those patients that are more likely to respond to the investigational new drug tivozanib.
This is possible, the researchers from AVEO Pharmaceuticals, Inc. said, because they have used a new way of creating animal tumor models that mimic tumor variation seen in human. Based on the results of these studies, they have found a single biomarker that may predict resistance to tivozanib, an oral, triple VEGF (vascular endothelial growth factor) receptor inhibitor.
Tivozanib is in an ...
Nanotechnology brings personalized therapy 1 step closer to reality
2010-09-29
DENVER — A novel technology can make nanoscale protein measurements, which scientists can use in clinical trials to learn how drugs work.
"We are making progress toward the goal of understanding how drugs work in different individuals," said Alice C. Fan, M.D., instructor in the division of oncology at Stanford University School of Medicine. "Using new technologies makes it possible to measure effects of therapeutic agents in tumor cells and different cell populations within our patients. Now that we can make these measurements, we are one step closer to being able to ...
Method to detect bladder cancer earlier is under development
2010-09-29
DENVER — Scientists may have discovered a way to diagnose bladder cancer at its earliest and, therefore, most treatable stages by measuring the presence or absence of microRNA using already available laboratory tests.
"Measuring expressions of microRNA in bodily fluid represents a very promising tool with widespread implications for screening," said Liana Adam, M.D., Ph.D., assistant professor in urology at The University of Texas MD Anderson Cancer Center.
Adam presented her findings at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic ...
c-Met may be a biomarker for metastatic hepatocellular carcinoma
2010-09-29
DENVER — Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma (HCC) who have c-Met-positive tumors, according to study results presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
HCC is the most common primary malignant tumor of the liver; c-Met is a receptor for hepatocyte growth factor that appears to drive liver cancer growth, invasion and metastasis.
"Current therapies for HCC patients are 'one size fits all.' We propose ...
LAST 30 PRESS RELEASES:
If you're over 60 and playing with sex toys, you're not alone
Fame itself may be critical factor in shortening singers’ lives
Daily coffee drinking may slow biological ageing of people with major mental illness
New highly efficient material turns motion into power – without toxic lead
The DEVILS in the details: New research reveals how the cosmic landscape impacts the galaxy lifecycle
After nearly 100 years, scientists may have detected dark matter
Gender imbalance hinders equitable environmental governance, say UN scientists
Six University of Tennessee faculty among world’s most highly cited researchers
A type of immune cell could hold a key to preventing scar tissue buildup in wounds
Mountains as water towers: New research highlights warming differences between high and low elevations
University of Tennessee secures $1 million NSF grant to build semiconductor workforce pipeline
Biochar shows powerful potential to build cleaner and more sustainable cities worldwide
UT Health San Antonio leads $4 million study on glucagon hormone’s role in diabetes, obesity
65-year-old framework challenged by modern research
AI tool helps visually impaired users ‘feel’ where objects are in real time
Collaborating minds think alike, processing information in similar ways in a shared task
Routine first trimester ultrasounds lead to earlier detection of fetal anomalies
Royal recognition for university’s dementia work
It’s a bird, it’s a drone, it’s both: AI tech monitors turkey behavior
Bormioli Luigi renews LionGlass deal with Penn State after successful trial run
Are developers prepared to control super-intelligent AI?
A step toward practical photonic quantum neural networks
Study identifies target for disease hyper progression after immunotherapy in kidney cancer
Concordia researchers identify key marker linking coronary artery disease to cognitive decline
HER2-targeted therapy shows promising results in rare bile duct cancers
Metabolic roots of memory loss
Clinical outcomes and in-hospital mortality rate following heart valve replacements at a tertiary-care hospital
Too sick to socialize: How the brain and immune system promote staying in bed
Seal milk more refined than breast milk
Veterans with cardiometabolic conditions face significant risk of dying during extreme heat events
[Press-News.org] Find New Customers Announces Webinar Series on B2B Marketing and Demand GenerationSeven out of 10 companies say lack of quality sales leads is no. 1 problem; "B2B Demand Generation Thought Leadership Series" designed to teach companies how to increase sales-ready leads.